Cyclin D1 Protein Overexpression in Extramedullary Plasmacytoma : A Clinicopathologic Study of 11 Cases

被引:0
作者
Kojima, Masaru [1 ]
Motoori, Tadashi [2 ]
Tamaki, Yoshio [3 ]
Igarashi, Tadahiko [4 ]
Matsumoto, Morio [5 ]
Shimizu, Kazuhiko [6 ]
Ogawa, Akira [7 ]
Itoh, Hideaki [8 ]
Asano, Shigeyuki [9 ]
Masawa, Nobuhide [1 ]
Inagaki, Hiroshi [10 ]
机构
[1] Dokkyo Univ, Sch Med, Dept Anat & Diagnost Pathol, 880 Kitakobayashi,Mibu Machi,Shimotsuga Gun, Mibu, Tochigi 3210293, Japan
[2] Kitazato Med Ctr Hosp, Dept Pathol, Kitamoto, Japan
[3] Gunma Canc Ctr Hosp, Dept Radiol, Ohta, Gunma, Japan
[4] Gunma Canc Ctr Hosp, Dept Hematol, Ohta, Gunma, Japan
[5] Natl Nishigunma Hosp, Dept Hematol, Shibukawa, Japan
[6] Ashikaga Red Cross Hosp, Dept Pathpl & Clin Labs, Ashikaga, Japan
[7] Natl Takasaki Hosp, Dept Pathpl & Clin Labs, Takasaki, Gunma, Japan
[8] Maebashi Red Cross Hosp, Dept Pathpl & Clin Labs, Maebashi, Gunma, Japan
[9] Iwaki Kyoritsu Hosp, Dept Pathol, Iwaki, Fukushima, Japan
[10] Nagoya City Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi, Japan
关键词
extramedullary plasmacytoma; cyclin D1; fluoresence in situ hybridization; immunohistochemistry;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:53 / 56
页数:4
相关论文
共 8 条
[1]  
Athanasiou E, 2001, AM J CLIN PATHOL, V116, P535
[2]   Immunohistochemical analysis identifies two cyclin D1+subsets of plasma cell myeloma, each associated with favorable survival [J].
Cook, JR ;
Hsi, ED ;
Worley, S ;
Tubbs, RR ;
Hussein, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (04) :615-624
[3]  
Grogan TM, 2001, WHO CLASSIFICATION T, P142
[4]  
Hussong JW, 1999, AM J CLIN PATHOL, V111, P111
[5]  
Kobayashi N, 2007, KITAKANTO MED J, V57, P251
[6]   Primary extramedullary plasmacytoma and multiple myeloma:: phenotypic differences revealed by immunohistochemical analysis [J].
Kremer, M ;
Ott, G ;
Nathrath, I ;
Specht, K ;
Stecker, K ;
Alexiou, C ;
Quintanilla-Martínez, L ;
Fend, F .
JOURNAL OF PATHOLOGY, 2005, 205 (01) :92-101
[7]   Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation [J].
Soverini, S ;
Cavo, M ;
Cellini, C ;
Terragna, C ;
Zamagni, E ;
Ruggeri, D ;
Testoni, N ;
Tosi, P ;
de Vivo, A ;
Amabile, M ;
Grafone, T ;
Ottaviani, E ;
Giannini, B ;
Cangini, D ;
Bonifazi, F ;
Neri, A ;
Fabris, S ;
Tura, S ;
Baccarani, M ;
Martinelli, G .
BLOOD, 2003, 102 (05) :1588-1594
[8]  
Vasef MA, 1997, MODERN PATHOL, V10, P927